<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04498676</url>
  </required_header>
  <id_info>
    <org_study_id>MS17.RIPT.P1200O.50.CBIO</org_study_id>
    <nct_id>NCT04498676</nct_id>
  </id_info>
  <brief_title>50 Human Subject Repeat Insult Patch Test</brief_title>
  <acronym>HRIPT</acronym>
  <official_title>50 Human Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Occlusive Patch)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAGE Bio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AMA Laboratories Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CAGE Bio Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Consumer products or raw materials designed for consistent reapplication to areas of the skin&#xD;
      may, under proper conditions, prove to be contact sensitizers or irritants in certain&#xD;
      individuals. It is the intention of a Repeat Insult Patch Test (RIPT) to provide a basis for&#xD;
      evaluation of this irritation/sensitization potential if such exists.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 18, 2017</start_date>
  <completion_date type="Actual">March 2, 2017</completion_date>
  <primary_completion_date type="Actual">February 8, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erythema</measure>
    <time_frame>21 days</time_frame>
    <description>Erythema rated on a numeric scale from 0 - 4. (0: None; 1: Minimal; 2: Mild; 3: Marked and 4: Severe erythema)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitisation</measure>
    <time_frame>24 hours</time_frame>
    <description>After a 10-14 day rest period, a challenge test was given at a different skin site to look for signals of a sensitization response measured by rating erythema on a scale from 0 - 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitisation</measure>
    <time_frame>48 hours</time_frame>
    <description>After a 10-14 day rest period, a challenge test was given at a different skin site to look for signals of a sensitization response measured by rating erythema on a scale from 0 - 4</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Erythema</condition>
  <condition>Sensitisation</condition>
  <arm_group>
    <arm_group_label>Test product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CB-0002B</intervention_name>
    <description>CB-0002B (choline geranate) is a viscous transparent colorless to light yellow liquid</description>
    <arm_group_label>Test product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals who are not currently under a doctor's care&#xD;
&#xD;
          -  Individuals free of any dermatological or systemic disorder which would interfere with&#xD;
             the results, at the discretion of the Investigator.&#xD;
&#xD;
          -  Individuals free of any acute or chronic disease that might interfere with or increase&#xD;
             the risk of study participation.&#xD;
&#xD;
          -  Individuals who will complete a preliminary medical history form mandated by AMA&#xD;
             Laboratories, Inc. and are in general good health.&#xD;
&#xD;
          -  Individuals, who will read, understand and sign an informed consent document relating&#xD;
             to the specific type of study they are subscribing. Consent forms are kept on file and&#xD;
             are available for examination on the premises of AMA Laboratories, Inc. only.&#xD;
&#xD;
          -  Individuals able to cooperate with the Investigator and research staff, willing to&#xD;
             have test materials applied according to the protocol, and complete the full course of&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals under 18 years of age.&#xD;
&#xD;
          -  Individuals who are currently under a doctor's care.&#xD;
&#xD;
          -  Individuals who are currently taking any medication (topical or systemic) that may&#xD;
             mask or interfere with the test results.&#xD;
&#xD;
          -  Subjects with a history of any acute or chronic disease that might interfere with or&#xD;
             increase the risk associated with study participation.&#xD;
&#xD;
          -  Individuals diagnosed with chronic skin allergies.&#xD;
&#xD;
          -  Female volunteers who indicate that they are pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>67 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director</last_name>
    <role>Study Director</role>
    <affiliation>AMA Laboratories Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AMA Laboratories Inc.</name>
      <address>
        <city>New City</city>
        <state>New York</state>
        <zip>10956</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>July 31, 2020</last_update_submitted>
  <last_update_submitted_qc>July 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HRIPT</keyword>
  <keyword>irritant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

